HERMAN, Dalibor, Pavel OSMANCIK, Petr NEUZIL, Pavel HALA, Veronika LEKESOVA, Klára BENEŠOVÁ, Marek HOZMAN, Jiří JARKOVSKÝ, Martina NOVÁČKOVÁ, Petr WIDIMSKY a V. Y. REDDY. The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY. HOBOKEN: WILEY, 2021, roč. 32, č. 10, s. 2645-2654. ISSN 1045-3873. Dostupné z: https://dx.doi.org/10.1111/jce.15206.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis
Autoři HERMAN, Dalibor (203 Česká republika), Pavel OSMANCIK (203 Česká republika, garant), Petr NEUZIL (203 Česká republika), Pavel HALA (203 Česká republika), Veronika LEKESOVA, Klára BENEŠOVÁ (203 Česká republika, domácí), Marek HOZMAN (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Martina NOVÁČKOVÁ (203 Česká republika, domácí), Petr WIDIMSKY (203 Česká republika) a V. Y. REDDY.
Vydání JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, HOBOKEN, WILEY, 2021, 1045-3873.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.942
Kód RIV RIV/00216224:14110/21:00123114
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1111/jce.15206
UT WoS 000688562000001
Klíčová slova anglicky atrial natriuretic peptide; biomarkers; brain natriuretic peptide; left atrial appendage; left atrial appendage closure
Štítky 14119612, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 6. 12. 2021 09:11.
Anotace
Introduction The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. Methods Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. Results There were no significant differences in baseline, 6 month, and delta (delta = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for delta in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for delta in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and delta concentrations of Galectin-3 and GDF-15 between the two groups. Conclusion LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.
VytisknoutZobrazeno: 12. 5. 2024 23:11